Go to the list of all blogs
Anna G's Avatar
published in Blogs
May 24, 2023
TickeronGET DAILY SIGNALS
Boston Scientific (BSX): Uptrend Continuation as Bullish Signals Emerge

Boston Scientific (BSX): Uptrend Continuation as Bullish Signals Emerge

Welcome to our analysis of Boston Scientific (BSX), a leading medical technology company that is currently experiencing a potential uptrend continuation. According to A.I.dvisor's predictions, BSX has entered a bullish trend, suggesting a favorable outlook for the stock. In this blog post, we will delve into the indicators supporting this forecast and analyze historical data, which indicates a strong probability of BSX's uptrend continuing.

Boston Scientific (BSX) is currently experiencing a projected uptrend, as indicated by A.I.dvisor's analysis. The forecast suggests that BSX may witness a growth of approximately 4%, potentially reaching a price of $55.83 or even higher within the next month. This projection underscores the positive sentiment surrounding the stock and indicates a strong likelihood of the uptrend continuing.

 Boston Scientific (BSX) is currently positioned in a monthly bullish trend, signaling a potential uptrend continuation. A.I.dvisor's analysis predicts growth in BSX's price within the next month, with statistical probabilities indicating an 82% chance of the uptrend continuing. Investors are advised to carefully evaluate their investment strategies, consider market dynamics, and consult with a qualified financial advisor before making any investment decisions.

At Tickeron, we believe in unleashing the power of artificial intelligence to enhance trading decisions, and our marketing team plays a pivotal role in sharing this vision with the world.

Related Ticker: BSX

BSX's Indicator enters downward trend

The Aroon Indicator for BSX entered a downward trend on October 14, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 126 similar instances where the Aroon Indicator formed such a pattern. In 88 of the 126 cases the stock moved lower. This puts the odds of a downward move at 70%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 33 of 67 cases where BSX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 49%.

The Momentum Indicator moved below the 0 level on October 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BSX as a result. In 49 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 54%.

The Moving Average Convergence Divergence Histogram (MACD) for BSX turned negative on October 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 26 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 58%.

BSX moved below its 50-day moving average on October 27, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BSX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.

BSX broke above its upper Bollinger Band on October 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BSX's RSI Indicator exited the oversold zone, 15 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 58%.

Following a +2.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where BSX advanced for three days, in 199 of 335 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 55 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. BSX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.576) is normal, around the industry mean (4.170). P/E Ratio (17.799) is within average values for comparable stocks, (1.500). Projected Growth (PEG Ratio) (0.618) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (3.117) is also within normal values, averaging (40.124).

The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 98 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BSX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.05B. The market cap for tickers in the group ranges from 837 to 190.62B. ABT holds the highest valuation in this group at 190.62B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -2%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was -9%. NSPR experienced the highest price growth at 45%, while BDMD experienced the biggest fall at -58%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was 8%. For the same stocks of the Industry, the average monthly volume growth was 0% and the average quarterly volume growth was -15%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 49
P/E Growth Rating: 50
Price Growth Rating: 61
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 15 (-100 ... +100)
View a ticker or compare two or three
BSX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a maker of medical devices

Industry MedicalNursingServices

Industry
Medical Specialties
Address
300 Boston Scientific Way
Phone
+1 508 683-4000
Employees
59000
Web
https://www.bostonscientific.com
Interact to see
Advertisement
The Bitwise Solana Staking ETF (BSOL) advanced roughly 18% over the trailing 30 days, closely tracking a sharp rally in Solana (SOL). The move extends a broader recovery, with BSOL up approximately 77% over the past three months from its mid-2026 trough.
MSTY is an actively managed single-stock option income ETF (exchange-traded fund) that writes call options on Strategy (MSTR), formerly MicroStrategy, to generate current income. The portfolio is anchored by U.S. Treasury bills and MSTR option contracts rather than a diversified basket of equities, concentrating exposure in one volatile underlying.
AMDL has surged roughly +64% over the past 30 days, from about $47.59 to $78.10, mirroring a powerful rally in its sole underlying stock, AMD . The fund is a leveraged single-stock ETF (exchange-traded fund) designed to deliver 2x the daily return of AMD, amplifying both gains and losses.
Analysts expect Q1 2026 revenue of approximately $8.5 billion, a roughly 5% increase from $8.1 billion in Q1 2025. Consensus adjusted earnings per share (EPS) forecast stands at $4.74, reflecting a potential decline from prior-year levels amid pricing pressures.
Analysts expect Q1 2026 adjusted EPS of around $1.61, down from prior year levels due to softer commodity prices. Consensus revenue forecast stands at approximately $14.5 billion, reflecting a year-over-year decline.